Orthofix International NV (NASDAQ:OFIX) – Research analysts at Gabelli upped their FY2017 EPS estimates for Orthofix International NV in a research note issued to investors on Wednesday. Gabelli analyst J. Tsai now anticipates that the medical device company will post earnings of $1.60 per share for the year, up from their prior forecast of $1.55. Gabelli also issued estimates for Orthofix International NV’s FY2018 earnings at $1.80 EPS, FY2019 earnings at $2.00 EPS and FY2021 earnings at $2.35 EPS.
Orthofix International NV (NASDAQ:OFIX) last issued its quarterly earnings data on Monday, October 30th. The medical device company reported $0.42 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.41 by $0.01. Orthofix International NV had a net margin of 0.33% and a return on equity of 10.26%. The firm had revenue of $105.30 million during the quarter, compared to the consensus estimate of $100.67 million. During the same quarter in the previous year, the firm posted $0.36 EPS. The company’s revenue for the quarter was up 6.9% compared to the same quarter last year. ILLEGAL ACTIVITY WARNING: This story was published by Community Financial News and is the property of of Community Financial News. If you are accessing this story on another site, it was copied illegally and republished in violation of international trademark and copyright law. The original version of this story can be viewed at https://www.com-unik.info/2017/11/04/orthofix-international-nv-expected-to-post-fy2017-earnings-of-1-60-per-share-ofix.html.
Several other research analysts also recently commented on OFIX. BidaskClub downgraded Orthofix International NV from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, July 25th. Zacks Investment Research upgraded Orthofix International NV from a “hold” rating to a “buy” rating and set a $54.00 target price for the company in a research note on Thursday, August 10th. TheStreet upgraded Orthofix International NV from a “c+” rating to a “b-” rating in a research note on Tuesday, August 8th. Jefferies Group LLC reiterated a “buy” rating and set a $55.00 target price (up from $50.00) on shares of Orthofix International NV in a research note on Thursday, August 10th. Finally, BTIG Research set a $56.00 target price on Orthofix International NV and gave the stock a “buy” rating in a research note on Monday, October 30th. Seven equities research analysts have rated the stock with a buy rating, The company currently has an average rating of “Buy” and a consensus price target of $54.42.
Shares of Orthofix International NV (NASDAQ:OFIX) opened at $51.89 on Thursday. Orthofix International NV has a 1 year low of $32.51 and a 1 year high of $54.33. The stock has a market cap of $946.02 million, a price-to-earnings ratio of 33.44, a PEG ratio of 2.57 and a beta of 0.15.
In related news, insider Raymond Fujikawa sold 6,364 shares of the business’s stock in a transaction on Thursday, August 10th. The stock was sold at an average price of $47.06, for a total value of $299,489.84. Following the completion of the sale, the insider now directly owns 31,084 shares in the company, valued at approximately $1,462,813.04. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Rice Doug sold 7,353 shares of the business’s stock in a transaction on Monday, September 11th. The shares were sold at an average price of $49.46, for a total value of $363,679.38. Following the completion of the sale, the chief financial officer now owns 44,743 shares of the company’s stock, valued at $2,212,988.78. The disclosure for this sale can be found here. Insiders sold a total of 23,406 shares of company stock valued at $1,138,531 over the last 90 days. 5.60% of the stock is currently owned by corporate insiders.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its stake in Orthofix International NV by 18.6% in the 1st quarter. Vanguard Group Inc. now owns 1,815,948 shares of the medical device company’s stock valued at $69,278,000 after purchasing an additional 284,482 shares during the period. Dimensional Fund Advisors LP raised its holdings in Orthofix International NV by 11.6% in the 2nd quarter. Dimensional Fund Advisors LP now owns 870,120 shares of the medical device company’s stock valued at $40,443,000 after acquiring an additional 90,349 shares in the last quarter. State Street Corp raised its holdings in Orthofix International NV by 4.1% in the 2nd quarter. State Street Corp now owns 481,220 shares of the medical device company’s stock valued at $22,370,000 after acquiring an additional 18,741 shares in the last quarter. Northern Trust Corp raised its holdings in Orthofix International NV by 5.8% in the 2nd quarter. Northern Trust Corp now owns 350,019 shares of the medical device company’s stock valued at $16,269,000 after acquiring an additional 19,253 shares in the last quarter. Finally, Teachers Advisors LLC raised its holdings in Orthofix International NV by 15.9% in the 2nd quarter. Teachers Advisors LLC now owns 320,404 shares of the medical device company’s stock valued at $14,892,000 after acquiring an additional 44,064 shares in the last quarter. Institutional investors and hedge funds own 93.80% of the company’s stock.
Orthofix International NV Company Profile
Orthofix International N.V. (Orthofix) is a global medical device company. The Company is focused on providing reconstructive and regenerative orthopedic and spine solutions to physicians. The company operates in four segments: BioStim, Biologics, Extremity Fixation and Spine Fixation. Its BioStim solutions products include Cervical-Stim, Spinal-Stim and Physio-Stim.
What are top analysts saying about Orthofix International NV? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Orthofix International NV and related companies.